Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Rating) CEO Dipal Doshi sold 2,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $12.00, for a total value of $24,000.00. Following the completion of the transaction, the chief executive officer now directly owns 208,710 shares of the company’s stock, valued at approximately $2,504,520. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Dipal Doshi also recently made the following trade(s):
- On Monday, June 27th, Dipal Doshi sold 4,000 shares of Entrada Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $48,000.00.
Entrada Therapeutics Stock Performance
Shares of Entrada Therapeutics stock opened at $12.80 on Friday. Entrada Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $36.85. The business has a 50-day moving average price of $9.70 and a 200 day moving average price of $9.28.
Institutional Investors Weigh In On Entrada Therapeutics
Large investors have recently bought and sold shares of the company. New York State Common Retirement Fund purchased a new stake in Entrada Therapeutics during the 1st quarter worth approximately $46,000. Bank of New York Mellon Corp increased its stake in Entrada Therapeutics by 60.6% during the 1st quarter. Bank of New York Mellon Corp now owns 21,933 shares of the company’s stock worth $206,000 after buying an additional 8,276 shares in the last quarter. Ghisallo Capital Management LLC purchased a new stake in Entrada Therapeutics during the 4th quarter worth approximately $257,000. Walleye Capital LLC purchased a new stake in Entrada Therapeutics during the 1st quarter worth approximately $419,000. Finally, Charles Schwab Investment Management Inc. increased its stake in Entrada Therapeutics by 7.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,704 shares of the company’s stock worth $646,000 after buying an additional 4,685 shares in the last quarter. 86.75% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group cut their price target on Entrada Therapeutics from $22.00 to $10.00 and set a “neutral” rating for the company in a research note on Tuesday, May 24th.
About Entrada Therapeutics
Entrada Therapeutics, Inc, a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1.
- Get a free copy of the StockNews.com research report on Entrada Therapeutics (TRDA)
- MarketBeat: Week in Review 7/25 – 7/29
- Procter’s Earnings Start To Show Weakness In Q4
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.